All In Biotech

Drug Trial Radar · NCT03673462

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Last checked: Nov 20, 2026Latest source record: Dec 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,797 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,797

Actual

Start

Sep 17, 2018

Primary completion

Mar 16, 2023

Study completion Mar 16, 2023

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study was to describe the safety profile of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) Conjugate Vaccine and Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 (MENVEO®) Conjugate Vaccine when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.

Conditions

  • Healthy Volunteers (Meningococcal Infection)

Interventions

  • Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)Biological

    Pharmaceutical form: Liquid solution. Route of administration: Intramuscular

  • Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)Biological

    Pharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular

  • Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b VaccineBiological

    Pharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular

  • Pneumococcal 13-valent Conjugate VaccineBiological

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • Rotavirus VaccineBiological

    Pharmaceutical form: Oral solution Route of administration: Oral

  • Hepatitis B VaccineBiological

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • Measles, Mumps, and Rubella Virus VaccineBiological

    Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous

  • Varicella Virus VaccineBiological

    Pharmaceutical form: Suspension for injection Route of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)Time frame: Within 30 minutes post-any vaccination
  2. Number of Participants With Solicited Injection Site ReactionsTime frame: Within 7 days post any vaccination
  3. Number of Participants With Solicited Systemic ReactionsTime frame: Within 7 days post-any vaccination
  4. Number of Participants With Unsolicited Adverse EventsTime frame: Within 30 days post any vaccination
  5. Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)Time frame: From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months)
  6. Number of Participants With Medically Attended Adverse Event (MAAEs)Time frame: From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months)

Locations

69 sites in 2 countries. Site status is shown where the registry gives one.

  • Birmingham Pediatric Associates-Site Number:8400049

    Birmingham, Alabama

  • Southeastern Pediatric Associates-Site Number:8400034

    Dothan, Alabama

  • MedPharmics, LLC - Phoenix-Site Number:8400043

    Phoenix, Arizona

  • Northwest Arkansas Pediatric Clinic-Site Number:8400042

    Fayetteville, Arkansas

  • HealthStar Research, LLC-Site Number:8400100

    Hot Springs, Arkansas

  • The Children's Clinic of Jonesboro, PA-Site Number:8400059

    Jonesboro, Arkansas

  • Emmaus Research Center, Inc-Site Number:8400057

    Anaheim, California

  • Advanced Clinical Research - Rancho Paseo-Site Number:8400087

    Banning, California

  • Premier Health Research Center, LLC-Site Number:8400039

    Downey, California

  • Center for Clinical Trials, LLC-Site Number:8400056

    Paramount, California

  • Center for Clinical Trials of San Gabriel-Site Number:8400051

    West Covina, California

  • Center for Clinical Trials of San Gabriel-Site Number:8400099

    West Covina, California

  • Optum Clinical Research-Site Number:8400076

    Colorado Springs, Colorado

  • IMMUNOe Research Centers - Thornton-Site Number:8400022

    Thornton, Colorado

  • Avail Clinical Research, LLC-Site Number:8400055

    DeLand, Florida

  • Advanced Research for Health Improvement-Site Number:8400096

    Fort Myers, Florida

  • Sarkis Clinical Trials-Site Number:8400003

    Gainesville, Florida

  • De Armas Research Center,-Site Number:8400088

    Miami, Florida

  • Healthy Life Research-Site Number:8400075

    Miami, Florida

  • Acevedo Clinical Research Associates-Site Number:8400032

    Miami, Florida

  • Crystal Biomedical Research-Site Number:8400018

    Miami Lakes, Florida

  • Advanced Research for Health Improvement-Site Number:8400005

    Naples, Florida

  • Meridian Clinical Research-Site Number:8400114

    Macon, Georgia

  • MOC Research-Site Number:8400095

    Mishawaka, Indiana

  • Kentucky Pediatics / Adult Research-Site Number:8400044

    Bardstown, Kentucky

  • University of Louisville-Site Number:8400082

    Louisville, Kentucky

  • Brownsboro Park Pediatrics-Site Number:8400040

    Louisville, Kentucky

  • All Children Pediatrics-Site Number:8400069

    Louisville, Kentucky

  • MedPharmics-Site Number:8400048

    Metairie, Louisiana

  • Pediatric Associates of Fall River-Site Number:8400103

    Fall River, Massachusetts

  • MedPharmics Biloxi-Site Number:8400052

    Biloxi, Mississippi

  • Craig Spiegel, MD-Site Number:8400067

    Bridgeton, Missouri

  • Center for Pharmaceutical Research-Site Number:8400080

    Kansas City, Missouri

  • Midwest Childrens Health Research Institute-Site Number:8400060

    Lincoln, Nebraska

  • Legacy Pediatrics-Site Number:8400004

    Rochester, New York

  • Medication Management-Site Number:8400072

    Greensboro, North Carolina

  • Ford, Simpson, Lively & Rice Pediatrics-Site Number:8400021

    Winston-Salem, North Carolina

  • Ohio Pediatric Research-Site Number:8400064

    Dayton, Ohio

  • PriMed Clinical Research-Site Number:8400033

    Dayton, Ohio

  • Senders Pediatrics-Site Number:8400061

    South Euclid, Ohio

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.